pdufa.bio
Home › Decisions › LNTH 2026-06-26

LNTH FDA decision: Jun 26, 2026

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET
✕ COMPLETE RESPONSE LETTER

Lantheus Holdings Inc., LNTH-2501 (Gallium-68 edotreotide).

Run-up into the decision (T-120 → T+5)

PDUFA 6/26/26$109.01$64.251/9/26
Daily close, T-120 (1/9/26) through T+5. Run-up high $109.01 on 6/25/26, low $64.25 on 1/23/26 (T-120 to T-1). FDA decision 6/26/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-26
OutcomeCRL
Drug / candidateLNTH-2501 (Gallium-68 edotreotide)
CompanyLantheus Holdings Inc.
120-day run-up (T-120→T-1)+62.0%

Primary source: Lantheus press release, June 26, 2026

Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.

Questions

Was LNTH-2501 (Gallium-68 edotreotide) approved by the FDA?

Not in this review cycle. A Complete Response Letter, declining to approve the application for LNTH-2501 (Gallium-68 edotreotide) in its current form, was announced on June 26, 2026. A CRL is not final; the primary source is linked on this page.

Which company is behind LNTH-2501 (Gallium-68 edotreotide)?

LNTH-2501 (Gallium-68 edotreotide) is a Lantheus Holdings Inc. (LNTH) program. The company announced the FDA decision on June 26, 2026; the company's own announcement is linked on this page.

How did LNTH stock trade into the FDA decision?

Measured over the 120 trading days before the decision (T-120 to T-1), LNTH moved +62.0%. That is the recorded price path into this specific event. Historical measurement, not a prediction, and not investment advice.